Strategies for overcoming chemotherapy resistance in cervical cancer from molecular insights to precision solutions /

Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer: From Molecular Insights to Precision Solutions, Volume 21 highlights different strategies to reverse chemotherapy resistance in cervical cancer. The book puts a strong focus on strategies to reverse chemotherapy resistance as well...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Dlamini, Zodwa
Format: eBook
Language:English
Published: London : Academic Press, 2024.
Series:Cancer Sensitizing Agents for Chemotherapy ; 21
Subjects:
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Intro
  • Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer: From Molecular Insights to Precision Solutions
  • Copyright
  • Cover Image Legend
  • Aims and Scope for Series ``Cancer Sensitizing Agents for Chemotherapy´´
  • About the Series Editor
  • Aims and Scope of the Volume
  • About the Volume Editor
  • Preface
  • Contents
  • Contributors
  • Chapter 1: An overview of cervical cancer, chemotherapy as treatment and chemotherapy resistance
  • Introduction
  • Staging for cervical cancer
  • The role of chemotherapy in the treatment of cervical cancer
  • Mode of action: Cisplatinum
  • The role of immunotherapy in the treatment of cervical cancer
  • Mode of action: Immunotherapy
  • Understanding the pathway for chemotherapy resistance
  • DNA methylation
  • Aberrant repair pathways
  • Stemness
  • Tumor microenvironment
  • Hypoxia
  • Classification of cisplatin resistance
  • Pretarget resistance
  • On-target resistance
  • Posttarget resistance
  • Off-target resistance
  • Overcoming chemotherapy resistance for future management of cervical cancer
  • Epigenetic regulators, and molecular therapies
  • Natural products from plants, and bioactive metabolites from micro-organisms used to overcome cancer resistance
  • Challenges for overcoming chemotherapy resistance in cervical cancer
  • Conclusion
  • References
  • Chapter 2: Current treatment options and limitations for cervical cancer
  • Introduction-Current approach to cervical cancer therapies
  • Chemotherapy regimens and their effectiveness
  • Targeted therapies and immunotherapies
  • Combination therapies and clinical trials
  • Limitations of current treatment options
  • Conclusions
  • References
  • Chapter 3: Radiotherapy treatment resistance in cervical cancer
  • Introduction
  • Conventional clinical-pathological factors
  • Patient-related factors
  • Treatment-related factors.
  • Tumor-related factors
  • Genomic markers of lymph node metastases
  • Pathological tumor type and treatment resistance
  • HPV and treatment resistance
  • HPV subtype
  • HPV viral load
  • HPV integration
  • Tumor hypoxia
  • Genetic alterations associated with treatment response
  • Limitations
  • Conclusion
  • References
  • Chapter 4: Mechanisms of chemotherapy resistance in cervical cancer
  • Background
  • The tumor microenvironment (TME) as an enabling environment in CC chemoresistance
  • Cancer stem cell activation
  • Cancer associated fibroblasts (CAFs) and immune cells
  • Tumor hypoxia in chemoresistance
  • Signaling pathways and epigenetics in CC chemoresistance
  • P53 pathway
  • PIP3K/Akt/MAPK pathway
  • EGFR pathway
  • Hippo pathway
  • SH3BP1 pathway
  • Metabolic alterations in chemoresistance
  • Combinatorial therapies in overcoming CC
  • Limitations and challenges of targeting cellular and molecular mechanisms in CC chemoresistance
  • Conclusions
  • References
  • Chapter 5: Reversal of resistance mechanisms in cervical cancer
  • Introduction
  • Identification of resistance mechanisms
  • Reduced uptake
  • Increased efflux
  • Thiol-containing protein-mediated inactivation
  • Increased DNA repair
  • Nucleotide excision repair
  • DNA mismatch repair
  • Inactivation of apoptosis pathways
  • Activation of EMT
  • Epigenetic factors
  • Stress response chaperones
  • Development of novel drugs and methods to target resistance mechanisms
  • Novel drugs for cervical cancer treatment
  • Overcoming resistance by drug delivery mechanisms
  • Liposomes
  • Hydrogels
  • Nanoparticles
  • Repurposing of existing drugs
  • Combination therapies to overcome resistance
  • Conclusion
  • References
  • Chapter 6: HPV- and HIV-associated epigenetic silencing in cervical cancer: Targets for overcoming chemoresistance
  • Introduction
  • HPV, HIV, and cervical cancer.
  • Mechanisms of HPV/HIV interaction in cervical cancer at a molecular level
  • HPV/host epigenetic modifications leading to chemoresistance in cervical cancer
  • DNA methylation and chemoresistance in cervical cancer
  • HPV genome methylation
  • Host genome methylation
  • Host methylation of apoptosis-associated genes
  • Host methylation of cell cycle-associated genes
  • DNA methylation of cell adhesion-associated genes
  • DNA methylation of cell differentiation and proliferation-associated genes
  • DNA methylation of DNA repair-associated genes
  • DNA methylation of cell signaling-associated genes
  • Histone acetylation
  • HPV histone acetylation
  • Host histone acetylation
  • Potential epigenetic biomarkers for cervical cancer treatment
  • Challenges and limitations of epigenetic biomarkers for cervical cancer treatment
  • Conclusion and future perspective
  • References
  • Chapter 7: Splicing-associated chemotherapy resistance in cervical cancer: Targeting splicing signatures
  • Introduction
  • Alternative splicing as a normal biological process
  • Dysregulated alternative splicing in cervical neoplasia and alterations in splicing regulatory factors
  • Alterations in splicing factors in CC
  • Alterations in hnRPNs in CC
  • Splicing and chemoresistance in CC
  • Deregulation of splicing factors leads to chemotherapy resistance in CC
  • CeRNA networks promote chemoresistance through alternative splicing regulation
  • LncRNAs splicing switch in CC chemoresistance
  • CircRNAs splicing switch in CC chemoresistance
  • siRNAs splicing switch in CC chemoresistance
  • PiRNAs splicing switch in CC chemoresistance
  • Limitations and challenges of targeting splicing signatures in alleviating CC chemoresistance
  • Conclusion
  • References.
  • Chapter 8: MicroRNA involvement in cervical cancer chemotherapy drug resistance: Restoring sensitivity to chemotherapeuti ...
  • Introduction
  • MicroRNAs-The potential cervical cancer treatment
  • Chemotherapy resistance and sensitivity
  • Application of miRNA in diagnosis and prognosis of cervical cancer
  • Challenges and limitations
  • Conclusion
  • References
  • Chapter 9: Future directions in cervical cancer treatment
  • Introduction
  • The roadmap to elimination of cervical cancer by 2030
  • Personalized medicine and precision oncology
  • Nanocarrier and drug-based delivery systems
  • Radiopharmaceutical therapy
  • Computational oncology
  • Artificial intelligence
  • Computational intelligence
  • Molecular targeted therapies
  • Monoclonal antibodies
  • Gene therapy
  • Indigenous knowledge systems
  • Identification of biomarkers for resistance
  • Challenges and limitations
  • Conclusion
  • References
  • Chapter 10: Conclusion: Overcoming chemoresistance in cervical cancer
  • Index.